So looks like we should see at least US$ 40 million of contracts signed in the financial year. So that means FY21 should be properly profitable .... a first for the company and hopefully a step on the road to it fulfilling its potential. Nice thing about the company is that its growth drivers are idiosyncratic so the impact from the economic fall out of the Coronavirus should be limited.
A bit of a rarity on the ASX these days a medtech company with a single digit P/E (for next year) and global leadership in an area of significant potential growth. Continued decent sales results and additional commercialization of Cognigram and over the next 18 months we could be looking at a shareprice that increases by multiples from here.
CGS Price at posting:
49.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)